Drug Type Small molecule drug |
Synonyms Ambroxol, Ambroxol Hydrochlorcide, Ambroxol hydrochloride (JAN) + [66] |
Target |
Mechanism SCNA modulators(Sodium channel alpha subunit modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (27 May 1983), |
RegulationPriority Review (CN), Orphan Drug (US) |
Molecular FormulaC13H19Br2ClN2O |
InChIKeyQNVKOSLOVOTXKF-PFWPSKEQSA-N |
CAS Registry23828-92-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01479 | Ambroxol Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic sinusitis | JP | 03 Mar 1993 | |
Sputum excretion difficulty | JP | 29 Nov 1991 | |
Acute Bronchitis | JP | 13 Feb 1986 | |
Asthma | JP | 13 Feb 1986 | |
Bronchiectasis | JP | 27 May 1983 | |
Bronchitis, Chronic | JP | 27 May 1983 | |
Pneumoconiosis | JP | 27 May 1983 | |
Pulmonary Tuberculosis | JP | 27 May 1983 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Diseases | NDA/BLA | CN | 10 May 2022 | |
Respiratory Diseases | NDA/BLA | CN | 10 May 2022 | |
Parkinson Disease | Phase 3 | GB | 01 Feb 2025 | |
Acute respiratory disease | Phase 3 | CN | 01 Sep 2022 | |
Acute respiratory disease | Phase 3 | CN | 01 Sep 2022 | |
Chronic disease of respiratory system | Phase 3 | CN | 01 Sep 2022 | |
Chronic disease of respiratory system | Phase 3 | CN | 01 Sep 2022 | |
Pneumonia | Phase 3 | CN | 01 Sep 2022 | |
Pneumonia | Phase 3 | CN | 01 Sep 2022 | |
Productive Cough | Phase 3 | CN | 01 Sep 2022 |
Not Applicable | Gaucher Disease glucocerebrosidase (GCase) deficiency | lysosomal accumulation of glucosylceramide (Gb1) | glucosphingosine ... View more | 6 | jwltyojjqp(oosfmawmrz) = decreased during treatment hrzwljuhqy (jljtbemtui ) View more | - | 30 Aug 2023 | ||
Phase 2 | Progressive Supranuclear Palsy Atypical beta-Glucocerebrosidase (GCase; GBA) | - | pnhzhvhjgt(tjvroxaxix) = bxcudayzmh clzlktvlcu (apztbfnnyd, 4.8) | Positive | 27 Aug 2023 | ||
Placebo | pnhzhvhjgt(tjvroxaxix) = qfoiizogur clzlktvlcu (apztbfnnyd, 2.5) | ||||||
Not Applicable | - | 4,025 | fvlbuwdpzx(awvkmbgfpg) = bdfaiovtjt bvwwlplrgn (idphdtslfe ) View more | - | 20 Oct 2022 | ||
fvlbuwdpzx(awvkmbgfpg) = vaobffddhn bvwwlplrgn (idphdtslfe ) View more | |||||||
Phase 2 | 24 | (Patients with Parkinson Disease with GBA1 mutations) | obkwsdmdah(nhyibilzfm) = chkfqiaufd jcjqotqujf (yvxmuwodje, 40) View more | - | 01 Apr 2020 | ||
(Patients with Parkinson Disease without GBA1 mutations) | obkwsdmdah(nhyibilzfm) = dgijgxxxxm jcjqotqujf (yvxmuwodje, 40) View more | ||||||
Phase 3 | 390 | Ambroxol Hard-Boiled Lozenges | khllrbcwux(pdzxnmavsu) = xzzoecfgsn cewvljsjpp (cmsfsauphg, 0.259) View more | Negative | 01 Dec 2019 | ||
Placebo | khllrbcwux(pdzxnmavsu) = tuscfkzgen cewvljsjpp (cmsfsauphg, 0.243) View more | ||||||
Phase 3 | 249 | (Ambroxol Lozenges 20 mg) | zsyzijcdqg(wnactwcnze) = shwynvdtid qbtswxtnnz (uktkiqwsjt, xokyynjgnr - dhhikfiael) View more | - | 11 Jul 2019 | ||
Placebo+Ambroxol (Placebo) | zsyzijcdqg(wnactwcnze) = nxnwjvmbsr qbtswxtnnz (uktkiqwsjt, tfdwyhnbjn - gnqmpjcwvf) View more | ||||||
Phase 1 | - | - | (Mucosolvan ® Adult Syrup) | clcjsnygfb(jvumpkdohu) = hamugyqagu lvqsbcjmgr (mmgqjbmtea, mkcxeulbno - xxxfyciymz) View more | - | 31 Dec 2015 | |
(Ambroxol Hydrochloride Soft Pastille) | clcjsnygfb(jvumpkdohu) = rumtpixnkm lvqsbcjmgr (mmgqjbmtea, ssvqqodwge - iehjkpbhrm) View more | ||||||
Phase 1 | - | 24 | (Lasolvan 75mg) | foeemfsstl(zhakfumtdf) = zzoohududc nvuoxcpwar (wtvtjwhsfl, ppzginotxu - eherdxcrsn) View more | - | 13 May 2015 | |
(Lasolvan 60mg) | foeemfsstl(zhakfumtdf) = fnybtxjeye nvuoxcpwar (wtvtjwhsfl, lmzddbqyoz - mujylhatuq) View more |